Recon: Pharma lawsuit challenging Medicare drug price negotiations dismissed; BioAge raises $170M for obesity combo

• Biogen sees flat 2024 sales, pick up in Alzheimer's drug demand (Reuters)
• A California court is setting a dangerous precedent over drug development (or lack thereof) liability (STAT)
• Judge tosses PhRMA lawsuit over Medicare power to negotiate drug prices (STAT) (Reuters)
• ‘Sleeper Issue:’ How Part B Drugs May Be Impacted By Medicare Part D Redesign (Pink Sheet)
• US FDA Oncology Diagnostics Pilot Is ‘Interim Step’ To Fill VALID Void, But ‘Stuck In Neutral’ (Pink Sheet)
• Biogen sees flat 2024 sales, pick up in Alzheimer's drug demand (Reuters)

• LianBio to shutter, ending Shanghai-based startup’s transatlantic ambitions (Endpoints)
• Mexico Launches ‘Regulatory Certainty Strategy’ For Biosimilars (Pink Sheet)
• WHO Tightens Up Guidance On Reserving Most Critical Antimicrobials For Humans Only (Pink Sheet)
• Swissmedic Asks Sponsors For At Least Four Months’ Notice Ahead Of New Drug Filings (Pink Sheet)
• Implementing The MDR And IVDR: Checkered History Signposts Need For Revised Approach (MedTech Insight)
• Progress Made With HTA Regulation Implementation Plan (MedTech Insight)

• Stem cell study offers clue to South Asians’ increased risk of cardiovascular disease (STAT)
• Eli Lilly partner BioAge raises $170 mln for obesity treatment (Reuters) (STAT)
• Ebola vaccine cuts fatality even in people who were infected before the jab, new study shows (STAT)
• Was Pfizer’s ‘Here’s to Science’ commercial during the Super Bowl a winning play or a fumble? (STAT)
• Pfizer’s Super Bowl Commercial Departs From Drug Ad Format (Pink Sheet)
• KalVista pill reduces swelling symptoms caused by genetic disease, achieving goal of late-stage study (STAT)
• Updated: Exscientia CEO brought down by allegations of inappropriate employee relationships, in blow to AI pioneer (Endpoints)
• Organon shelves contraceptive with 'natural' estrogen (Endpoints)
• Amgen doubles down on ‘bad’ cholesterol awareness with new campaign, free testing (Endpoints)
• Roivant discontinues blood cancer program as it fails to revive old Eisai drug, to dissolve Hemavant (Endpoints)
• BMS, VantAI team up; CRISPR Therapeutics to raise $280M; Ono Pharma's deal with Shattuck Labs (Endpoints)
• EyeBio targets registrational trial after early success of Wnt agonist in retinal diseases (Endpoints)
• Lingering Leqembi Question: When Should Treatment Stop? (Pink Sheet)

• FDA Says PCCPs Are Possibility For Sterilization Changes (MedTech Insight)
• FDA AdCom Will Scrutinize Placebo Benefit Of Abbott’s TriClip G4 TTVR (MedTech Insight)
• eXeX Claims ‘World First’: Apple’s Mixed-Reality Headset Deployed As Logistics Tool In OR (MedTech Insight)

• No one’s pleased with the government’s pitch for 2025 Medicare Advantage rates (STAT)
• Has Oscar finally figured out its health insurance business? (Endpoints)